Cargando…
Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons
PURPOSE: Radiation therapy (RT) is the standard treatment for patients with inoperable skin malignancies of the head and neck region (H&N), and as adjuvant treatment post surgery in patients at high risk for local or regional recurrence. This study reports clinical outcomes of intensity-modulate...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Particle Therapy Co-operative Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270091/ https://www.ncbi.nlm.nih.gov/pubmed/34285955 http://dx.doi.org/10.14338/IJPT-20-00045.1 |
_version_ | 1783720727495573504 |
---|---|
author | Bridhikitti, Jidapa Viehman, Jason K. Harmsen, W. Scott Amundson, Adam C. Shiraishi, Satomi Mundy, Daniel W. Rwigema, Jean-Claude M. McGee, Lisa A. Patel, Samir H. Routman, David M. Lester, Scott C. Neben-Wittich, Michelle A. Garces, Yolanda I. Ma, Daniel J. Foote, Robert L. |
author_facet | Bridhikitti, Jidapa Viehman, Jason K. Harmsen, W. Scott Amundson, Adam C. Shiraishi, Satomi Mundy, Daniel W. Rwigema, Jean-Claude M. McGee, Lisa A. Patel, Samir H. Routman, David M. Lester, Scott C. Neben-Wittich, Michelle A. Garces, Yolanda I. Ma, Daniel J. Foote, Robert L. |
author_sort | Bridhikitti, Jidapa |
collection | PubMed |
description | PURPOSE: Radiation therapy (RT) is the standard treatment for patients with inoperable skin malignancies of the head and neck region (H&N), and as adjuvant treatment post surgery in patients at high risk for local or regional recurrence. This study reports clinical outcomes of intensity-modulated proton therapy (IMPT) for these malignancies. MATERIALS AND METHODS: We retrospectively reviewed cases involving 47 patients with H&N malignancies of the skin (squamous cell, basal cell, melanoma, Merkel cell, angiosarcoma, other) who underwent IMPT for curative intent between July 2016 and July 2019. Overall survival was estimated via Kaplan-Meier analysis, and oncologic outcomes were reported as cumulative incidence with death as a competing risk. RESULTS: The 2-year estimated local recurrence rate, regional recurrence rate, local regional recurrence rate, distant metastasis rate, and overall survival were 11.1% (95% confidence interval [CI], 4.1%-30.3%), 4.4% (95% CI, 1.1%-17.4%), 15.5% (95% CI, 7%-34.3%), 23.4% (95% CI, 5.8%-95.5%), and 87.2% (95% CI, 75.7%-100%), respectively. No patient was reported to have a grade 3 or higher adverse event during the last week of treatment or at the 3-month follow-up visit. CONCLUSION: IMPT is safe and effective in the treatment of skin malignancies of the H&N. |
format | Online Article Text |
id | pubmed-8270091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Particle Therapy Co-operative Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-82700912021-07-19 Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons Bridhikitti, Jidapa Viehman, Jason K. Harmsen, W. Scott Amundson, Adam C. Shiraishi, Satomi Mundy, Daniel W. Rwigema, Jean-Claude M. McGee, Lisa A. Patel, Samir H. Routman, David M. Lester, Scott C. Neben-Wittich, Michelle A. Garces, Yolanda I. Ma, Daniel J. Foote, Robert L. Int J Part Ther Clinical PURPOSE: Radiation therapy (RT) is the standard treatment for patients with inoperable skin malignancies of the head and neck region (H&N), and as adjuvant treatment post surgery in patients at high risk for local or regional recurrence. This study reports clinical outcomes of intensity-modulated proton therapy (IMPT) for these malignancies. MATERIALS AND METHODS: We retrospectively reviewed cases involving 47 patients with H&N malignancies of the skin (squamous cell, basal cell, melanoma, Merkel cell, angiosarcoma, other) who underwent IMPT for curative intent between July 2016 and July 2019. Overall survival was estimated via Kaplan-Meier analysis, and oncologic outcomes were reported as cumulative incidence with death as a competing risk. RESULTS: The 2-year estimated local recurrence rate, regional recurrence rate, local regional recurrence rate, distant metastasis rate, and overall survival were 11.1% (95% confidence interval [CI], 4.1%-30.3%), 4.4% (95% CI, 1.1%-17.4%), 15.5% (95% CI, 7%-34.3%), 23.4% (95% CI, 5.8%-95.5%), and 87.2% (95% CI, 75.7%-100%), respectively. No patient was reported to have a grade 3 or higher adverse event during the last week of treatment or at the 3-month follow-up visit. CONCLUSION: IMPT is safe and effective in the treatment of skin malignancies of the H&N. The Particle Therapy Co-operative Group 2021-06-25 /pmc/articles/PMC8270091/ /pubmed/34285955 http://dx.doi.org/10.14338/IJPT-20-00045.1 Text en ©Copyright 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/Distributed under Creative Commons CC-BY (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Clinical Bridhikitti, Jidapa Viehman, Jason K. Harmsen, W. Scott Amundson, Adam C. Shiraishi, Satomi Mundy, Daniel W. Rwigema, Jean-Claude M. McGee, Lisa A. Patel, Samir H. Routman, David M. Lester, Scott C. Neben-Wittich, Michelle A. Garces, Yolanda I. Ma, Daniel J. Foote, Robert L. Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons |
title | Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons |
title_full | Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons |
title_fullStr | Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons |
title_full_unstemmed | Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons |
title_short | Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons |
title_sort | oncologic outcomes for head and neck skin malignancies treated with protons |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270091/ https://www.ncbi.nlm.nih.gov/pubmed/34285955 http://dx.doi.org/10.14338/IJPT-20-00045.1 |
work_keys_str_mv | AT bridhikittijidapa oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT viehmanjasonk oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT harmsenwscott oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT amundsonadamc oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT shiraishisatomi oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT mundydanielw oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT rwigemajeanclaudem oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT mcgeelisaa oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT patelsamirh oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT routmandavidm oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT lesterscottc oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT nebenwittichmichellea oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT garcesyolandai oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT madanielj oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons AT footerobertl oncologicoutcomesforheadandneckskinmalignanciestreatedwithprotons |